Avalanche Announces Phase 2 Wet AMD Trial Headed Back To The Lab
August 14, 2015 at 21:34 PM EDT
Shares of Avalanche tumbled today 27% after the company reported that it won't advance its phase 2 AVA-101 Wet AMD gene therapy treatment for the time being
